<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00276315</url>
  </required_header>
  <id_info>
    <org_study_id>A-38-52120-074</org_study_id>
    <nct_id>NCT00276315</nct_id>
  </id_info>
  <brief_title>Assessment of Effectiveness and Safety of Dysport® for the Treatment of Hemifacial Spasm</brief_title>
  <official_title>A Phase III, Multicentre, Randomised, Assessor-Blind, Parallel Groups, Reference Drug Controlled Study to Assess the Efficacy and Safety of a Single Administration, by Subcutaneous Injection of Dysport® for the Treatment of Hemifacial Spasm</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ipsen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ipsen</source>
  <brief_summary>
    <textblock>
      To compare the effectiveness and safety of Dysport® with the domestic Botulinum Toxin Type A
      (manufactured by Lanzhou Biologic Product Institute, P.R. China) for the treatment of
      hemifacial spasm.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">January 2007</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of responders (defined as Cohen scale improvement ≥ to 2 levels)</measure>
    <time_frame>At the end of week 4</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of responders (defined as Cohen scale improvement ≥ to 2 levels after medication)</measure>
    <time_frame>At the end of week 1 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement degree of spasm (Jankovic scale)</measure>
    <time_frame>At the end of week 1, 4 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of efficacy by the subjects</measure>
    <time_frame>At the end of week 1, 4 and 12</time_frame>
  </secondary_outcome>
  <enrollment>348</enrollment>
  <condition>Hemifacial Spasm</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botulinum type A toxin (Dysport®) - one single injection</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient suffering from hemifacial spasm with at least 6 months duration (prior to
             visit 1)

          -  Cohen scale ≥ to grade II

        Exclusion Criteria:

          -  Botulinum toxin type A treatment history within last 16 weeks prior to visit 1

          -  Hemifacial spasm secondary to facial palsy

          -  Previous alcohol or phenol injections or surgical therapy of the facial muscles

          -  Requirement for botulinum toxin injection to site(s) of the body other than in this
             study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jing-dong Ma, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ipsen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Neurology Department, Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology Department, Guangdong Provincial People's Hospital</name>
      <address>
        <city>Guangdong</city>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology Department, Sir Run Run Shaw Hospital, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <zip>310016</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology Department, Shanghai Ruijin Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 12, 2006</study_first_submitted>
  <study_first_submitted_qc>January 12, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2006</study_first_posted>
  <last_update_submitted>July 23, 2007</last_update_submitted>
  <last_update_submitted_qc>July 23, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 25, 2007</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spasm</mesh_term>
    <mesh_term>Hemifacial Spasm</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>abobotulinumtoxinA</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>onabotulinumtoxinA</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

